Home/Pipeline/Kinesia as Digital Endpoint

Kinesia as Digital Endpoint

Movement Disorder Clinical Trials

Commercial/ServiceActive

Key Facts

Indication
Movement Disorder Clinical Trials
Phase
Commercial/Service
Status
Active
Company

About Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies is a private, revenue-generating medical device company specializing in digital biomarkers and remote monitoring for neurological conditions, particularly movement disorders. The company has established a commercial product line, Kinesia, which is used in clinical care, deep brain stimulation (DBS) management, and as an objective endpoint in global clinical trials. Its growth is supported by NIH SBIR grants and a growing patent portfolio covering AI-driven symptom measurement and treatment adjustment, positioning it at the intersection of neurology, telemedicine, and decentralized clinical trials.

View full company profile